Anti-CD20 (Ofatumumab biosimilar - IgG1 isotype)

Product Unit size Cat. code Docs. Qty. Price


Human CD20 (Ofatumumab) antibody - Human IgG1

Show product

100 µg

1 mg


Human IgG1 monoclonal antibody (mAb) against human CD20

Effector functions of mAb isotypes targeting CD20

Anti-hCD20-Of-hIgG1 is the biosimilar of the clinical antibody ofatumumab. Anti-hCD20-Of-hIgG1 features the constant region (Fc) of a human IgG1 isotype and the variable region of ofatumumab. Ofatumumab targets the human CD20 antigen found on the surface of normal and malignant B lymphocytes.

Ofatumumab is a fully human type I (first generation) monoclonal antibody that mediates B cell destruction through complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). Ofatumumab has been approved by the FDA to treat chronic lymphocytic leukemia (CLL)  [1-3].


InvivoGen’s Anti-hCD20-Of-hIgG1 is generated by recombinant DNA technology, produced in Chinese hamster ovary (CHO) cells, and purified by affinity chromatography (protein G).
More isotypes of this antibody are available and can be used to compare several biological activities such as ADCC (see below or in the 'upon request' section).
InvivoGen also provides type I and type II anti-hCD20 mAbs featuring the variable regions of Rituximab or Obinutuzumab, with either native or engineered Fc region.


 Read our review on Antibody Isotypes



1. Baig NA. et al., 2014. Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia. J Immunol. 192(4):1620-9.
2. Lin TS., 2010. Ofatumumab: a novel monoclonal anti-CD20 antibody. Pharmgenomics Pers Med. 3:51-9.
3. Winiarska M. et al., 2011. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci (Landmark Ed). 16:277-306.


CD20 cell surface staining using Anti-hCD20-Of-hIgG1
CD20 cell surface staining using Anti-hCD20-Of-hIgG1

Binding of Anti-hCD20-Of-hIgG1 mAb to hCD20. EL4-hCD20 cells were incubated for 30 minutes at 4°C with 500 ng of Anti-hCD20-Of-hIgG1 or an isotype control. Subsequently, a secondary PE-labeled antibody was added and incubated at 4°C for 30 minutes. The binding affinity was assessed using flow cytometry

Back to the top


Target: Human CD20

Clonality: Monoclonal antibody

Clone: Ofatumumab (Anti-hCD20-hIgG1, kappa)

Isotype: Human IgG1, kappa

Control: Human IgG1

Source: CHO cells

Formulation: 0.2 µm filtered solution in 68 mM sodium phosphate buffer (pH 7.4) with 91 mM glycine, 5% w/v saccharose and stabilizing agents

Purity: Purified by affinity chromatography with protein G

Tested application: Flow cytometry

Quality control:

  • Binding of Anti-hCD20-Of-hIgG1 to human CD20 has been tested using flow cytometry.
  • The complete sequence of this antibody has been verified.
  • The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.
Back to the top


Anti-hCD20-Of-hIgG1 purified monoclonal antibody is provided azide-free and lyophilized. It is available in two quantities:

  • hcd20of-mab1: 100 µg
  • hcd20of-mab1-1: 1 mg

room temperature Anti-hCD20-Of-hIgG1 is shipped at room temperature.

store Upon receipt, store lyophilized antibody at -20 °C.



Tags: buy Ofatumumab (Anti-CD20) | Ofatumumab (Anti-CD20) supplier | purchase Ofatumumab (Anti-CD20) | Ofatumumab (Anti-CD20) cost | Ofatumumab (Anti-CD20) manufacturer | order Ofatumumab (Anti-CD20) | Ofatumumab (Anti-CD20) distributor

Back to the top
Customer Service
& Technical Support
Shopping cart is empty